A research technician at the Research and Production Center of Physics (NPCF) of the RFNC-VNIIEF (enterprise of the Rosatom State Corporation), where the device is designed and manufactured, Ivan Murzin showed the cardiocenter doctors the capabilities of the new equipment and demonstrated all the functionality of the device.
"Tianox" is the world's first device that synthesizes nitric oxide from the air, right at the patient's bedside. Inhalations with nitric oxide are effective in intensive therapy of critical conditions caused by pulmonary hypertension and are used in surgical correction of heart defects, including in young children, as well as in diseases with right ventricular insufficiency.
Nitric oxide therapy is well controlled – the effect develops two minutes after the start of the gas supply and ends 4-8 minutes after termination, which is not present, for example, with treatment with other drugs. What is important is that the use of nitric oxide is not accompanied by a decrease in blood pressure."Tianox" can be used both for patients on a ventilator and those on independent breathing. The device does not require special conditions and storage space.
Currently, serial production of "Tianox" devices with a capacity of 200 units per year, warranty and post-warranty service is organized on the basis of the NPCF. In 2022, certificates of conformity of the quality management system GOST ISO 13485-2017 and ISO 13485: 2016 were obtained for all processes of the life cycle of the device.
Currently, Tianox devices are successfully used in more than 50 medical institutions in Russia. To date, thousands of cardiac surgeries are performed with their use. The device is widely used for the treatment of the new coronavirus infection COVID-19, both in the active phase of the disease, and in the complex therapy of patients with postcovid syndrome. In 2022, "Tianox" was included in the standard equipment of neonatology centers. In the near future, it is planned to launch the device on international markets.